Literature DB >> 8953315

Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes.

K A Choate1, T M Kinsella, M L Williams, G P Nolan, P A Khavari.   

Abstract

Therapeutic gene delivery in severe genetic skin disease may require production of a uniformly corrected population of cells capable of regeneration of normal skin elements when returned to the host. To achieve this, we have used lamellar ichthyosis (LI), a disorder of epidermal differentiation recently associated with defects in keratinocyte transglutaminase (TGase1), as a prototype. We have used a high-efficiency retroviral delivery approach to uniformly restore normal levels of TGase1 expression to primary keratinocytes from severely affected LI patients previously lacking TGase1. Delivered TGase1 was correctly targeted to membrane association and restored patient cell transglutaminase activity levels to normal. Corrected primary LI patient keratinocytes also demonstrated restoration of previously defective involucrin cross-linking and in vitro measures of cornification to levels found in normal cells. These results indicate that efficient TGase1 delivery to early passage keratinocytes can produce a population of corrected LI patient cells. The capability to produce such cells may provide a basis for future efforts at gene therapy for genetic skin disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953315     DOI: 10.1089/hum.1996.7.18-2247

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

Review 1.  Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders.

Authors:  Matthias Schmuth; Robert Gruber; Peter M Elias; Mary L Williams
Journal:  Adv Dermatol       Date:  2007

2.  Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB.

Authors:  C S Seitz; Q Lin; H Deng; P A Khavari
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  Cultivation of human keratinocyte stem cells: current and future clinical applications.

Authors:  G Pellegrini; S Bondanza; L Guerra; M De Luca
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

4.  In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa.

Authors:  P B Robbins; Q Lin; J B Goodnough; H Tian; X Chen; P A Khavari
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

5.  NF-kappaB determines localization and features of cell death in epidermis.

Authors:  C S Seitz; R A Freiberg; K Hinata; P A Khavari
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Evidence for keratinocyte stem cells in vitro: long term engraftment and persistence of transgene expression from retrovirus-transduced keratinocytes.

Authors:  T M Kolodka; J A Garlick; L B Taichman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

Review 7.  Progress in Intradermal and Transdermal Gene Therapy with Microneedles.

Authors:  Ting Zhu; Wenya Zhang; Pengju Jiang; Shuwen Zhou; Cheng Wang; Lin Qiu; Honglei Shi; Pengfei Cui; Jianhao Wang
Journal:  Pharm Res       Date:  2022-08-25       Impact factor: 4.580

8.  Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression.

Authors:  Jason A Reuter; Susana Ortiz-Urda; Markus Kretz; John Garcia; Florence A Scholl; Anna M G Pasmooij; David Cassarino; Howard Y Chang; Paul A Khavari
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

9.  Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue.

Authors:  Zurab Siprashvili; Ngon T Nguyen; Maria Y Bezchinsky; M Peter Marinkovich; Alfred T Lane; Paul A Khavari
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

Review 10.  Challenges in Treating Genodermatoses: New Therapies at the Horizon.

Authors:  Marie-Anne Morren; Eric Legius; Fabienne Giuliano; Smail Hadj-Rabia; Daniel Hohl; Christine Bodemer
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.